

Table SI. Baseline characteristics of patients with refractory to first-line GCS treatment (n=57).

Factors	Second-line chemotherapy (n=30)	Best supportive care (n=27)	p-value
Age (years)	66 (39 – 78)	66 (56 – 80)	0.6535
Gender			>0.9999
Male	16 (53)	14 (52)	
Female	14 (47)	13 (48)	
Primary Tumor site			0.2322
Gall bladder	10 (33)	13 (48)	
Extrahepatic bile duct	10 (33)	8 (30)	
Intrahepatic bile duct	10 (33)	6 (22)	
Ampullary	0 (0)	0 (0)	
Disease stage			0.5551
Unresectable	23 (77)	21 (78)	
Locally advanced	4 (13)	1 (4)	
Metastatic	19 (63)	20 (74)	
Recurrent	7 (23)	6 (22)	
GCS duration (weeks)	26 (2 - 84)	24 (4 - 79)	0.3757
GCS duration \geq 24 weeks	18 (60)	13 (48)	0.4311

Data are median (range), or number (%). GCS, Gemcitabine, Cisplatin plus S-1.

Table SII. Baseline characteristics of patients with intolerance to first-line GCS treatment (n=26).

Factors	Second-line chemotherapy (n=21)	Best supportive care (n=5)	p-value
Age (years)	69 (42 – 81)	75 (67 – 81)	0.1012
Gender			0.6169
Male	12 (57)	4 (80)	
Female	9 (43)	1 (20)	
Primary Tumor site			0.2524
Gall bladder	3 (14)	2 (40)	
Extrahepatic bile duct	11 (52)	2 (40)	
Intrahepatic bile duct	6 (29)	1 (20)	
Ampullary	1 (5)	0 (0)	
Disease stage			0.9187
Unresectable	12 (57)	3 (60)	
Locally advanced	4 (19)	1 (20)	
Metastatic	8 (38)	2 (40)	
Recurrent	9 (43)	2 (40)	
GCS duration (weeks)	18 (0 - 63)	9 (5 - 30)	0.1963
GCS duration \geq 24 weeks	7 (33)	1 (20)	>0.9999

Data are median (range), or number (%). GCS, Gemcitabine, Cisplatin plus S-1.